: This letter to the editor outlines the use of stereotactic body radiotherapy for metastatic renal cell carcinoma in the U.S., identifying clinical predictors of utilization using the National Cancer Database.
Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S
Paciotti, Marco
;
2021-01-01
Abstract
: This letter to the editor outlines the use of stereotactic body radiotherapy for metastatic renal cell carcinoma in the U.S., identifying clinical predictors of utilization using the National Cancer Database.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
